Epitopea clôture un tour de table de 14 millions de dollars pour la découverte d'antigènes tumoraux
Epitopea Ltd. raised $13.6 million in seed financing to take forward a new cancer immunotherapy platform based on the identification of a new class of tumor-specific antigens encoded by non-canonical genomic sequences.
The Cambridge, U.K.-based firm is building on the academic research of company co-founders Claude Perrault and Pierre Thibault, both based at the Institute for Research in Immunology and Cancer at the Université de Montréal. In a series of papers, Perrault, Thibault, and colleagues have described novel tumor antigens encoded by what were previously considered non-coding gene sequences, including long-noncoding RNAs, short open reading frames and pseudogenes.
Pour lire l'article complet, cliquez ici (PDF, s'ouvre dans un nouvel onglet)
